Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients

Journal of Inflammation

Volumn 7, Issue , 2010, Pages

  Tanni, Suzana E ^a   Pelegrino, Nilva R G ^a   Angeleli, Aparecida Y O ^a   Correa, Camila ^a   Godoy, Irma ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; C REACTIVE PROTEIN; CORTICOSTEROID; INTERLEUKIN 6; INTERLEUKIN 8; OXYGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY COMPOSITION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PROTEIN BLOOD LEVEL; SMOKING; SPIROMETRY;

EID: 77953208012     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-7-29     Document Type: Article

References (40)

1. The neutrophil in chronic obstructive pulmonary disease. JK Quint JA Wedzicha, J Allergy Clin Immunol 2007 119 1065 1071 10.1016/j.jaci.2006.12.640 17270263
2. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. E Gamble DC Grootendorst K Hattotuwa T O'Shaughnessy FSF Ram Y Qiu, et al. Eur Respir J 2007 30 467 471 10.1183/09031936.00013006 17504799
3. Neutrophilic infiltration within the airway smooth muscle in patients with COPD. S Baraldo G Turato C Badin E Bazzan B Beghe R Zuin, et al. Thorax 2004 59 308 312 10.1136/thx.2003.012146 15047950
4. Differential distribution of inflammatory cells in large and small airways in smokers. S Battaglia T Mauad AM van Schadewijk AM Vignola KF Rabe V Bellia, et al. J Clin Pathol 2007 60 907 911 10.1136/jcp.2006.037002 16917001
5. Natural-History of Chronic Air-Flow Obstruction. C Fletcher R Peto, Br Med J 1977 1 1645 1648 10.1136/bmj.1.6077.1645 871704
6. Developing COPD: a 25 year follow up study of the general population. A Løkke P Lange H Scharling P Fabricius J Vestbo, Thorax 2006 61 935 939 10.1136/thx.2006.062802 17071833 (Pubitemid 44787161)
7. Systemic effects of chronic obstructive pulmonary disease. AG Agustí A Noguera J Sauleda E Sala JXB Pons, Eur Respir J 2003 21 347 360 10.1183/09031936.03.00405703 12608452
8. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. WQ Gan SFP Man A Senthilselvan DD Sin, Thorax 2004 59 574 580 10.1136/thx.2003.019588 15223864
9. Markers of disease severity in chronic obstructive pulmonary disease. LG Franciosi CP Page BR Celli M Cazzola MJ Walker M Danhot, et al. Pulm Pharmacol & Ther 2006 19 189 199
10. Circulating leptin in patients with chronic obstructive pulmonary disease. N Takabatake H Nakamura S Abe T Hino H Saito H Yuki, et al. Am J Respir Crit Care Med 1999 159 1215 1219 10194168
11. C-reactive protein in patients with COPD, control smokers and non-smokers. VM Pinto-Plata H Mullerova JF Toso M Feudjo-Tepie JB Soriano RS Vessey, et al. Thorax 2006 61 23 28 10.1136/thx.2005.042200 16143583
12. Systemic inflammation in chronic obstructive pulmonary disease and asthma: Similarities and differences. Y Higashimoto Y Yamagata S Taya T Iwata M Okada T Ishiguchi, et al. Respirology 2008 13 128 133 18197923
13. Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. A Churg J Dai H Tai CS Xie JL Wright, Am J Respir Crit Care Med 2002 166 849 854 10.1164/rccm.200202-097OC 12231496
14. Role of TNF-alpha in pulmonary pathophysiology. S Mukhopadhyay JR Hoidal TK Mukherjee, Respir Res 2006 7 125 10.1186/1465-9921-7-125 17034639
15. Raised CRP levels mark metabolic and functional impairment in advanced COPD. R Broekhuizen EF Wouters ECAS Creutzberg, Thorax 2006 61 17 22 10.1136/thx.2005.041996 16055618
16. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. JH Vernooy M Kucukaycan JA Jacobs NH Chavannes WA Buurman MA Dentener, et al. Am J Respir Crit Care Med 2002 166 1218 1224 10.1164/rccm.2202023 12403691
17. GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary updated 2006. http://www.goldcopd.org
18. Changes in the normal maximal expiratory flow-volume curve with growth and aging. RJ Knudson MD Lebowitz CJ Holberg B Burrows, Am Rev Respir Dis 1983 127 725 734 6859656
19. Composition of the ESPEN Working Group. Bioelectrical impedance analysis-part I: review of principles and methods. UG Kyle I Bosaeus AD De Lorenzo P Deurenberg M Elia JM Gámez, et al. Clin Nutr 2004 23 1226 1243 10.1016/j.clnu.2004.06.004 15380917
20. New bioelectrical impedance formula for patients with respiratory insufficiency: comparison to dual-energy X-ray absorptiometry. UG Kyle C Pichard T Rochat DO Slosman JW Fitting D Thiebaud, Eur Respir J 1998 12 960 966 10.1183/09031936.98.12040960 9817176
21. Single prediction equation for bioelectrical impedance analysis in adults aged 20-94 years. UG Kyle L Genton L Karsegard DO Slosman C Pichard, Nutrition 2001 17 248 253 10.1016/S0899-9007(00)00553-0 11312069
22. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. A Schols PB Soeters AMC Dingemans R Mostert PJ Frantzen EFM Wouters, Am Rev Respir Dis 1993 147 1151 1156 8484624
23. Manual of SigmaStat 3.5 for Windows. SigmaStat, 2006 Chapter 8 308 326
24. The role of TNF superfamily members in T-cell function and disease. M Croft, Nat Rev Immunol 2009 9 271 85 10.1038/nri2526 19319144
25. Tumour necrosis factor and cancer. F Balkwill, Nat Rev Cancer 2009 9 361 71 10.1038/nrc2628 19343034
26. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. TC O'Shaughnessy TW Ansari NC Barnes PK Jeffery, Am J Respir Crit Care Med 1997 155 852 7 9117016
27. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. M Saetta A Di Stefano G Turato FM Facchini L Corbino CE Mapp, et al. Am J Respir Crit Care Med 1998 157 822 826 9517597
28. Cellular and structural bases of chronic obstructive pulmonary disease. M Saetta G Turato P Maestrelli CE Mapp LM Fabbri, Am J Respir Crit Care Med 2001 163 1304 1309 11371392
29. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. VM Keatings PD Collins DM Scott PJ Barnes, Am J Respir Crit Care Med 1996 153 530 534 8564092
30. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. S Takanashi Y Hasegawa Y Kanehira K Yamamoto K Fujimoto K Satoh, et al. Eur Respir J 1999 14 309 314 10.1034/j.1399-3003.1999.14b12.x 10515406
31. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. B Barcelá J Pons JM Ferrer J Sauleda A Fuster AG Agustí Eur Respir J 2008 31 555 562 10.1183/09031936.00010407 18057064
32. Pulmonary biomarkers in chronic obstructive pulmonary disease. PJ Barnes B Chowdhury SA Kharitonov H Magnussen CP Page D Postma, et al. Am J Respir Crit Care Med 2006 174 6 14 10.1164/rccm.200510-1659PP 16556692 (Pubitemid 43955238)
33. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. BWM Willemse NHT ten Hacken B Rutgers I Lesman-Leegte DS Postma W Timens, Eur Respir J 2005 26 835 845 10.1183/09031936.05.00108904 16264044
34. INTERHEART Study Investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. KK Teo S Ounpuu S Hawken MR Pandey V Valentin D Hunt, et al. Lancet 2006 368 647 658 10.1016/S0140-6736(06)69249-0 16920470
35. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. P Tønnesen L Carrozzi KO Fagerström C Gratziou C Jimenez-Ruiz S Nardini, et al. Eur Respir J 2007 29 390 417 10.1183/09031936.00060806 17264326
36. Cytokines and dietary energy restriction in stable chronic obstructive pulmonary disease patients. I Godoy AO Campana RR Geraldo CR Padovani SA Paiva, Eur Respir J 2003 22 920 925 10.1183/09031936.03.00025303 14680079
37. Inverse association between pulmonary function and C-reactive protein in apparently healthy subjects. D Aronson I Roterman M Yigla A Kerner O Avizohar R Sella, et al. Am J Respir Crit Care Med 2006 174 626 632 10.1164/rccm.200602- 243OC 16778162
38. Catabolic/anabolic balance and muscle wasting in patients with COPD. R Debigare K Marquis CH Cote RR Tremblay A Michaud P LeBlanc, et al. Chest 2003 124 83 89 10.1378/chest.124.1.83 12853506
39. Possible mechanisms underlying the development of cachexia in COPD. PD Wagner, Eur Respir J 2008 31 492 501 10.1183/09031936.00074807 18310396
40. Elevated TNF production in whole blood in patients with sever COPD: the potential link to disease severity. S von Haehling NS Hopkinson MI Polkey M Niethammer SD Anker S Genth-Zotz, Wien Klin Wochesnschr 2009 121 303 308 10.1007/s00508-009-1186-7